Tight glycemic control (TGC) has emerged as a major research focus in critical care due to its potential to simultaneously reduce both mortality and costs. However, repeating initial successful TGC trials that reduced mortality and other outcomes has proven difficult with more failures than successes. Hence, there has been growing debate over the necessity of TGC, its goals, the risk of severe hypoglycemia, and target cohorts. This paper provides a review of TGC via new analyses of data from several clinical trials, including SPRINT, Glucontrol and a recent NICU study. It thus provides both a review of the problem and major background factors driving it, as well as a novel model-based analysis designed to examine these dynamics from a new perspective. Using these clinical results and analysis, the goal is to develop new insights that shed greater light on the leading factors that make TGC difficult and inconsistent, as well as the requirements they thus impose on the design and implementation of TGC protocols. A model-based analysis of insulin sensitivity using data from three different critical care units, comprising over 75,000h of clinical data, is used to analyse variability in metabolic dynamics using a clinically validated model-based insulin sensitivity metric (S(I)). Variation in S(I) provides a new interpretation and explanation for the variable results seen (across cohorts and studies) in applying TGC. In particular, significant intra- and inter-patient variability in insulin resistance (1/S(I)) is seen be a major confounder that makes TGC difficult over diverse cohorts, yielding variable results over many published studies and protocols. Further factors that exacerbate this variability in glycemic outcome are found to include measurement frequency and whether a protocol is blind to carbohydrate administration.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cmpb.2010.11.006 | DOI Listing |
Chembiochem
January 2025
Nankai University, Institute of Polymer Chemistry, CHINA.
Diabetes is a metabolic disorder characterized by insufficient endogenous insulin production or impaired sensitivity to insulin. In recent years, a class of incretin-based hypoglycemic drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), have attracted great attention in the management of type 2 diabetes mellitus (T2DM) due to their benefits, including stable glycemic control ability, a low risk of hypoglycemia, and weight reduction for patients. However, like other peptide drugs, GLP-1RAs face challenges such as instability, susceptibility to enzymatic degradation, and immunogenicity, which severely limit their clinical application.
View Article and Find Full Text PDFDiabetes Obes Metab
January 2025
Department of Medicine, Division of Endocrinology, Diabetes Research Center, Columbia University Irving Medical Center, New York, New York, USA.
Objective: Post-prandial glucose response (PPGR) is a risk factor for cardiovascular disease. Meal carbohydrate content is an important predictor of PPGR, but dietary interventions to mitigate PPGR are not always successful. A personalized approach, considering behaviour and habitual pattern of glucose excursions assessed by continuous glucose monitor (CGM), may be more effective.
View Article and Find Full Text PDFBackground And Objectives: Metabolic disease has become a global health concern, and insulin resistance (IR) is a crucial underlying mechanism in various metabolic diseases. This study aims to compare the ability of seven anthropometric indicators in predicting IR in the Chinese population, and to find more sensitive and simple anthropometric indicator for early identification of IR.
Methods: This prospective cross-sectional study obtained participants' medical history, anthropometric indicators, and serum samples from three hospitals in China.
Front Endocrinol (Lausanne)
January 2025
Department of Orthopedics, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
Osteoarthritis (OA) is a prevalent condition that affects individuals worldwide and is one of the leading causes of disability. Nevertheless, the underlying pathological mechanisms of OA remain inadequately understood. Current treatments for OA include non-drug therapies, pharmacological interventions, and surgical procedures.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
January 2025
Sports Medicine Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Background: The relationship of insulin resistance with bone mineral density (BMD) remains unclear, offering an opportunity for novel indices to shed light on the matter. The aim of this review was to evaluate the association between surrogate indices of insulin resistance and BMD.
Methods: A systematic review was conducted to evaluate observational studies that examined the relationship between insulin resistance surrogate indices and BMD in adults.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!